Symptomatology during previous SARS-CoV-2 infection and serostatus before vaccination influence the immunogenicity of BNT162b2 COVID-19 mRNA vaccine by Sabryna Nantel, Sabryna Nantel, Benoîte Bourdin, Kelsey Adams, Julie Carbonneau, Julie Carbonneau, Henintsoa Rabezanahary, Henintsoa Rabezanahary, Henintsoa Rabezanahary, Marie-Ève Hamelin, Marie-Ève Hamelin, Deirdre McCormack, Patrice Savard, Patrice Savard, Yves Longtin, Matthew P. Cheng, Gaston De Serres, Gaston De Serres, Gaston De Serres, Jacques Corbeil, Jacques Corbeil, Vladimir Gilca, Vladimir Gilca, Vladimir Gilca, Mariana Baz, Mariana Baz, Mariana Baz, Guy Boivin, Guy Boivin, Caroline Quach, Caroline Quach, Hélène Decaluwe, Hélène Decaluwe, Hélène Decaluwe

Get full text